<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896023</url>
  </required_header>
  <id_info>
    <org_study_id>154</org_study_id>
    <nct_id>NCT02896023</nct_id>
  </id_info>
  <brief_title>Predictors of Ovarian Reserve in Infertile Women</brief_title>
  <official_title>Sonographic and Laboratory Predictors of Ovarian Reserve in Infertile Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be subjected to:

      A. Clinical evaluation including history and examination

      B. Ultrasonographic evaluation of Ovarian Morphometry:

        -  Patients will be evaluated in early follicular phase of the menstrual flow (cycle's days
           1-3) by TVS scanning; using MINDRAY DP-1100 Plus Digital Machine, 7.5MHz, China, by only
           one examiner to avoid inter-observer variations.

        -  Ovarian images will be procured in the sagittal and coronal planes and the frozen image
           reflecting the largest ovarian dimensions will be utilized for the measurement of
           ovarian length, width, and height (cm) as per standard clinical practice. Mean values of
           both ovaries will be used. Ovarian volume will be calculated from ellipsoid volume
           formula, {Ovarian volume = Ovarian Width (D1) × Ovarian Length (D2) ×Ovarian Height (D3)
           × 0 .523}

        -  Antral follicle count will be determined for each patient

      C. Laboratory Evaluation:

      Blood samples will be collected in the early follicular phase. Samples will be immediately
      centrifuged and serum saved at -20 degrees for measurement of:

        -  Anti Mullerian Hormone (AMH)

        -  Follicle Stimulating Hormone (FSH)

        -  Estradiol (E2) Using electro-chemiluminescence immunoassay (ELICA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be subjected to:

      A. Clinical evaluation including history and examination

      B. Ultrasonographic evaluation of Ovarian Morphometry:

        -  Patients will be evaluated in early follicular phase of the menstrual flow (cycle's days
           1-3) by TVS scanning; using MINDRAY DP-1100 Plus Digital Machine, 7.5MHz, China, by only
           one examiner to avoid inter-observer variations.

        -  Ovarian images will be procured in the sagittal and coronal planes and the frozen image
           reflecting the largest ovarian dimensions will be utilized for the measurement of
           ovarian length, width, and height (cm) as per standard clinical practice. Mean values of
           both ovaries will be used. Ovarian volume will be calculated from ellipsoid volume
           formula, {Ovarian volume = Ovarian Width (D1) × Ovarian Length (D2) ×Ovarian Height (D3)
           × 0 .523}

        -  Antral follicle count will be determined for each patient

      C. Laboratory Evaluation:

      Blood samples will be collected in the early follicular phase. Samples will be immediately
      centrifuged and serum saved at -20 degrees for measurement of:

        -  Anti Mullerian Hormone (AMH)

        -  Follicle Stimulating Hormone (FSH)

        -  Estradiol (E2) Using electro-chemiluminescence immunoassay (ELICA)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positive pregnancy test</measure>
    <time_frame>14 days after embryo transfer</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>pregnant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women with positive pregnancy test after induction of ovulation and ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not pregnant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women with negative pregnancy test after induction of ovulation and ICSI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human menopausal gonadotropin</intervention_name>
    <description>Induction of ovulation followed by ICSI</description>
    <arm_group_label>pregnant</arm_group_label>
    <arm_group_label>Not pregnant</arm_group_label>
    <other_name>menogon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  less than 39 years old,

          -  normal menstrual cycle with a range of 24 to 35 days

          -  normal seum prolactin.

          -  normal uterine cavity determined by previous hysterosalpingography or hysteroscopy

        Exclusion Criteria:

          -  smokers

          -  endometriosis

          -  Women with endometriosis;

          -  abnormal endocrine functions such as diabetes mellitus, thyroid disorders, and adrenal
             abnormalities; general diseases, those with ovarian cysts, or those who have
             azospermia partners.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Maged, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr Alainy medical school</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Maged, MD</last_name>
    <phone>01005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Maged</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>predictors</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>infertile women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

